Literature DB >> 24995689

Excess mortality on the liver transplant waiting list: unintended policy consequences and Model for End-Stage Liver Disease (MELD) inflation.

Patrick Grant Northup1, Nicolas Michael Intagliata, Neeral Lalit Shah, Shawn Joseph Pelletier, Carl Lansing Berg, Curtis Kent Argo.   

Abstract

UNLABELLED: The Model for End-Stage Liver Disease (MELD) allocation system for liver transplantation provides "exceptions" for diseases such as hepatocellular carcinoma (HCC). It was the aim of this study to assess equipoise between exception candidates and nonexception candidates on the waiting list and to assess if the exception system contributes to steadily increasing regional MELD at transplant. In all, 78,595 adult liver transplant candidates between January 2005 and December 2012 were analyzed. Yearly trends in waiting list characteristics and transplantation rates were analyzed for statistical association with MELD exceptions. Regional variations in these associations and the effect of exceptions on regional MELD scores at transplant were also analyzed. 27.29% of the waiting list was occupied by candidates with exceptions. Candidates with exceptions fared much better on the waiting list compared to those without exceptions in mean days waiting (HCC 237 versus non-HCC 426), transplantation rates (HCC 79.05% versus non-HCC 40.60%), and waiting list death rates (HCC 4.49% versus non-HCC 24.63%). Strong regional variation in exception use occurred but exceptions were highly correlated with waiting list death rates, transplantation rates, and MELD score at removal in all regions. In a multivariate model predicting MELD score at transplant within regions, the percentage of HCC MELD exceptions was the strongest independent predictor of regional MELD score at transplant.
CONCLUSION: Liver transplant candidates with MELD exceptions have superior outcomes compared to nonexception candidates and the current MELD exception system is largely responsible for steadily increasing MELD scores at transplant independent of geography.
© 2014 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2014        PMID: 24995689     DOI: 10.1002/hep.27283

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  34 in total

Review 1.  Liver Allocation Policies in the USA: Past, Present, and the Future.

Authors:  Anjana Pillai; Thomas Couri; Michael Charlton
Journal:  Dig Dis Sci       Date:  2019-04       Impact factor: 3.199

2.  Liver transplantation and waitlist mortality for HCC and non-HCC candidates following the 2015 HCC exception policy change.

Authors:  Tanveen Ishaque; Allan B Massie; Mary G Bowring; Christine E Haugen; Jessica M Ruck; Samantha E Halpern; Madeleine M Waldram; Macey L Henderson; Jacqueline M Garonzik Wang; Andrew M Cameron; Benjamin Philosophe; Shane Ottmann; Anne F Rositch; Dorry L Segev
Journal:  Am J Transplant       Date:  2018-11-09       Impact factor: 8.086

3.  Magnetic Spiderman, a New Surgical Training Device: Study of Safety and Educational Value in a Liver Transplantation Surgical Training Program.

Authors:  Yue Wang; Huan Chen; Bo Tang; Tao Ma; Qingshan Li; Haoyang Zhu; Xiaogang Zhang; Yi Lv; Dinghui Dong
Journal:  World J Surg       Date:  2020-04       Impact factor: 3.352

Review 4.  Intravenous immunoglobulins in liver transplant patients: Perspectives of clinical immune modulation.

Authors:  Arno Kornberg
Journal:  World J Hepatol       Date:  2015-06-18

Review 5.  Model for end-stage liver disease score and MELD exceptions: 15 years later.

Authors:  Sumeet K Asrani; Patrick S Kamath
Journal:  Hepatol Int       Date:  2015-05-28       Impact factor: 6.047

6.  Patient-reported outcomes in liver transplant recipients with hepatocellular carcinoma.

Authors:  Clark D Kensinger; Irene D Feurer; Heather W O'Dell; David C LaNeve; Lindsey Simmons; C Wright Pinson; Derek E Moore
Journal:  Clin Transplant       Date:  2016-07-18       Impact factor: 2.863

7.  Patients With Hepatocellular Carcinoma Have Highest Rates of Wait-listing for Liver Transplantation Among Patients With End-Stage Liver Disease.

Authors:  David Goldberg; Benjamin French; Craig Newcomb; Qing Liu; Gurvaneet Sahota; Anna E Wallace; Kimberly A Forde; James D Lewis; Scott D Halpern
Journal:  Clin Gastroenterol Hepatol       Date:  2016-06-29       Impact factor: 11.382

8.  Repopulation of intrahepatic bile ducts in engineered rat liver grafts.

Authors:  Yibin Chen; Julie Devalliere; Beyza Bulutoglu; Martin L Yarmush; Basak E Uygun
Journal:  Technology (Singap World Sci)       Date:  2019-06-28

9.  Poor Performance Status Is Associated With Increased Mortality in Patients With Cirrhosis.

Authors:  Eric S Orman; Marwan Ghabril; Naga Chalasani
Journal:  Clin Gastroenterol Hepatol       Date:  2016-04-01       Impact factor: 11.382

Review 10.  Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches.

Authors:  Gonzalo Sapisochin; Jordi Bruix
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-01-05       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.